MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients

NCT04032626 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Cognitive Impairment, Mild
Cognitive Dysfunction
Amyloid Plaque
Neurodegeneration
Inflammation, Brain

Interventions

DRUG: Lenalidomide 10 mg
DRUG: Placebo

Sponsor

St. Joseph's Hospital and Medical Center, Phoenix

Collaborators

[object Object]
[object Object]